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Infection of the colon with the Gram-positive bacterium Clostridium difficile is 
potentially life threatening, especially in elderly people and in patients who have 
dysbiosis of the gut microbiome following antimicrobial drug exposure. C. difficile is the 
 Smits et al 2 
 
leading cause of infective healthcare-associated diarrhoea. The lifecycle of C. difficile is 
influenced by the host microbiota and its associated metabolites, antimicrobial agents 
and the host immune system. The primary mediators of inflammation in C. difficile 
infection (CDI) are the large clostridial toxins Toxin A (TcdA) and Toxin B (TcdB), [CE: 
please leave abbreviations in for field preference] and, in some bacterial strains, the 
binary toxin CDT. The toxins trigger a complex cascade of host cellular responses to 
cause diarrhoea, inflammation and tissue necrosis — the major symptoms of CDI. The 
factors responsible for the epidemic of some C. difficile strains are poorly understood. 
Recurrent infections are common and can be debilitating. Toxin detection for diagnosis 
is important for accurate epidemiological study, and optimal management and 
prevention strategies. Infections are commonly treated with specific antimicrobial 
agents, but faecal microbiota transplants have shown promise for recurrent infections. 
Future biotherapies for C. difficile infections are likely to involve defined combinations 
of key gut microbiota. 
 
[H1] Introduction 
Clostridium difficile is a Gram-positive obligate anaerobic bacterium that was originally 
identified as part of the flora of healthy infants in 1935, described as an ‘actively motile, 
heavy-bodied rod with elongated subterminal or nearly terminal spores’1 (Figure 1). At 
that time, the strain was named Bacillus difficilis to reflect the difficulty experienced by 
the authors in isolating and culturing it. Despite the organism being present as a 
commensal in neonates, researchers noted that it could induce disease in animals that 
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was probably caused by the production of a secreted toxin1. Later work established the 
high molecular weight clostridial toxins, Toxin A (TcdA) and/or Toxin B (TcdB) as the 
main virulence (disease-causing) factors of C. difficile2,3. A hallmark feature of C. difficile 
that sets it apart from other species in the class Clostridia is its ability to decarboxylate 
parahydroxyphenylacetic acid to produce p-cresol, which gives C. difficile its 
characteristic tar-like or pig-like smell4.  
 
It was not until the 1970s that a detailed characterization of the bacterium, then called 
C. difficile, revealed its involvement in human disease5. This disease became widely 
known as C. difficile associated disease/diarrhoea (CDAD); more recently, the term ‘C. 
difficile infection’ (CDI) is preferred. In the early 2000s, an increase in severe cases of 
CDI was noted in Canada, the United States and Europe6 that was attributed to the 
emergence of certain epidemic types of C. difficile7,8. The first complete genome 
sequence for C. difficile9, together with the development of tools for the genetic 
manipulation of C. difficile10,11, has greatly stimulated research on the bacterium. C. 
difficile is now recognized as the leading cause of infective healthcare-associated 
diarrhoea and is increasingly linked to community-acquired cases of colitis12. C. difficile 
can be found in the intestinal tract of both humans and animals, but its spores are also 
ubiquitous in the environment and can be isolated from food13. Importantly, people 
with an adequate immune response will either eliminate the infection and/or become 
asymptomatic carriers14. In 2013, it was proposed that C. difficile should be reclassified 
as Peptoclostridium difficile on the basis of a detailed phylogenetic analysis15and this has 
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been adopted by the National Center for Biotechnology Information. However, 
considering the public awareness of the disease, the large body of scientific literature 
using C. difficile, and the lack of formal acceptance of this proposal, we will refer to the 
organism as C. difficile throughout this Primer, and to the disease it causes as CDI. We 
describe key aspects of the epidemiology of C. difficile infections, the mechanisms 
behind the disease, strategies for diagnosis, prevention and management and 
summarize the impact CDIs have on patients and society. 
 
[H1] Epidemiology 
Molecular typing (Box 1) is the characterization beyond the species level, enabling 
clustering of individual bacterial isolates in a meaningful manner16. Typing is crucial for 
epidemiological studies, and facilitates effective infection prevention and disease 
management. Different types of C. difficile are known; here, we will refer to PCR 
ribotypes when relevant, a typing system that is based on a banding pattern obtained 
from PCR amplifying ribosomal 16S-23S intergenic spacer sequences17. Certain PCR 
ribotypes of C. difficile (such as PCR ribotype 010) are non-pathogenic, as they lack the 
toxin genes. Epidemic PCR ribotypes are distinguished from non-epidemic types by their 
frequent occurrence in multiple settings across several countries.  
 
Due to a lack of systematic surveillance, no comprehensive data are available on 
circulating C. difficile types prior to 2003. After 2003, large increases in incidence and 
mortality rates in North America — and subsequently in several European countries — 
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were observed, which were associated with PCR ribotype 027 (Ref. 8) and, to a lesser 
extent, PCR ribotype 078 (Ref. 7). Such increases have also been observed in Australia, 
Asia and Central America after 2008 (Ref.18). It should be noted, however, that CDI and 
CDI-related epidemics are not limited to these types. Ribotypes 001, 002 and 014/020 
frequently cause CDI clusters in the United States and Europe19,20. Furthermore, 
outbreaks have also been reported for strains of other PCR ribotypes, such as 017 
(Ref.12), 018 (Ref. 21), 106 (Ref. 12), 176 (Ref. 22) and 244 (Ref. 23). Epidemiological data on 
C. difficile in Africa and the Middle-East are sparse12. 
 
CDI is historically regarded as a nosocomial infection; antibiotic exposure (either 
prophylactic or as treatment) during hospitalization is the foremost risk factor for CDI.  
However, C. difficile is increasingly being recognized as a cause of community-associated 
diarrhoea. Indeed, PCR ribotypes of strains isolated from patients with community-
associated CDI have a large overlap with strains cultured from patients with healthcare-
associated CDI in an endemic setting, suggesting a common source (or sources) of C. 
difficile24,25. The incidence of community-associated CDI is estimated at 30 to 120 cases 
per 100,000 persons per year in the United States26. The incidence of community-
associated CDI in The Netherlands is estimated at 390 to 730 per 100,000 person years, 
similar to the incidence of Campylobacter spp. infection, and higher than the incidence 
of Salmonella spp. infection27 More than 30% of patients who developed community-
associated CDI do not have typical risk factors for CDI, such as antibiotic treatment or 
recent hospitalization (see below)28,29.  
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The US Centers for Disease Control and Prevention (CDC) estimated almost 500,000 
patients with CDI and 29,000 deaths in the United States in 2011 (Ref. 26); however, 
there is uncertainty about the precision of these estimates given the accuracy of testing 
methodology, although data have been adjusted based on the frequency of nucleic acid 
amplification test use. Between 2001 and 2010, the incidence of CDI among hospitalized 
adults in the United States approximately doubled, according to International 
Classification of Diseases (ICD)-9 discharge diagnoses30. Again, ascertainment bias 
secondary to awareness (frequency of requesting) and to diagnostic methods could be 
relevant here.  
 
The first European Centre for Disease Prevention and Control (ECDC) point prevalence 
survey in 2011-2012 estimated that ~124,000 patients develop healthcare-associated 
CDI within the European Union each year31. However, this surveillance was performed 
with a variety of diagnostic tests and CDI was often only tested upon physician request, 
resulting in considerable underestimation of the true CDI incidence; on average, 
approximately 80 cases of CDI are missed per hospital per annum in Europe32. A pilot 
study supported by the ECDC using standardized CDI surveillance performed in 37 
hospitals in 14 European countries demonstrated large differences in the incidence of 
CDI per hospital and per country33. The incidence of healthcare-associated CDI by 
hospital was in the range 4.2–131.8 per 10,000 discharges (median 16.4 per 10,000 
discharges) and 0.6–18.5 per 10,000 patient-days (median 3.7 per 10,000 patient-days). 
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In some countries, a high incidence of PCR ribotype 027 strains has been noted, but 
other countries demonstrated a decrease in the incidence of these strains, most likely as 
a consequence of effective management strategies (see below)32.  
 
The all-cause mortality associated with CDI due to non-epidemic PCR ribotypes has been 
reported to be ~15-20% within a month of diagnosis, and about half of the deaths are 
due directly to CDI34. Given the multiple co-morbidities (such as respiratory disease and 
renal failure) typically present in patients with CDI, mortality is often related to one or 
more of these.  
 
 
C. difficile is a human pathogen and can also infect and cause disease in animals that can 
enter the food chain, but the relevance of food-born transmission in human disease is 
unclear13. Since the beginning of 2000, C. difficile has been reported as a major cause of 
neonatal enteritis in piglets. The predominant strains found in piglets (belonging to PCR 
ribotype 078) are similar to isolates from some human patients with CDI and to isolates 
from asymptomatic farm workers, suggesting zoonotic transmission13,35. As a 
consequence of increasing pressure from spores present in the environment and 
animals, humans might become colonized more frequently. One meta-analysis revealed 
an increased rate (>8% of admitted patients) of asymptomatic colonization by toxigenic 
isolates in patients at the time of admission to the hospital36. It should be noted, 
however, that patients admitted to the hospital frequently have had prior hospital 
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exposures and, therefore, have a much higher colonization than people in the 
community. 
 
[H1] Mechanisms/pathophysiology  
[H2] C. difficile lifecycle 
C. difficile is transmitted via the oral–faecal route (Figure 2). Spores are dormant cells 
that are highly resistant to environmental conditions37, including many antimicrobials 
(Box 2) — which generally target metabolically active cells — and some disinfectants. 
Spores are thought to be the infectious vehicle, given that vegetative (metabolically 
active) cells of obligate anaerobic bacteria are unlikely to survive the oxygenated 
environment outside the host or the acidic environment of the stomach. Indeed, an 
asporogenic strain of C. difficile is unable to persist in the environment or transmit 
between hosts38.  
 
Germination of spores is dependent on sensing of primary bile acids from the liver, such 
as taurocholate, by the germinant receptor CspC and is inhibited by secondary bile acids 
in the colon37,39,40. Additionally, glycine can act as a germinant via an uncharacterized 
mechanism41. A proteolytic cascade then leads to the degradation of the spore 
peptidoglycan, release of calcium dipicolinic acid and rehydration of the spore — 
ultimately resulting in outgrowth of the cells37,40.  
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The propensity of spores to outgrow and colonize the intestine is greatly influenced by 
the host microbiota and its associated metabolome39,42. For example, antibiotic-induced 
shifts in the microbiota can generate an environment conducive to C. difficile infection43. 
Mucolytic enzymes, such as cell surface protein Cwp84 (Ref. 44), are secreted by the 
bacterium and degrade the colonic mucosa. Bacterial cell surface-associated proteins 
have been shown to affect the adhesion of the bacterium to colon epithelial cells in 
vitro45–48; mutations in genes encoding these proteins, or in the genes encoding proteins 
for their processing, generally attenuate virulence49,50. The expression of at least a 
subset of colonization factors by the bacteria, such as cell surface protein Cwp84 and 
surface layer protein A (SlpA), is stimulated in the presence of antibiotics ampicillin and 
clindamycin51.  
 
Before germination into vegetative cells, spores are also capable of adhering to colon 
cells53. C. difficile is a motile bacterium, and the switch between the sessile and motile 
phase is regulated by the secondary messenger cyclic-di-GMP54–56. C. difficile is also 
capable — at least in vitro — of forming robust biofilms57–59. Cell–cell signalling 
contributes to both colonization and virulence factor expression60,61. Host recognition of 
C. difficile is mediated via pattern recognition receptors and MYD88- and nucleotide-
binding oligomerization domain-containing protein 1 (NOD1)-dependent pathways62,63 
(Figure 3). Specifically, SlpA can activate a Toll-like receptor 4 (TLR4)-dependent 
response64, flagellin can stimulate TLR5 (Ref.65) and NOD1 is likely activated via 
peptidoglycan-derived compounds66. The first line of host defence against C. difficile is 
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the production of antimicrobial compounds such as lysozyme and cationic antimicrobial 
peptides67,68. Interestingly, the bactericidal α-defensins, but not β-defensin 1 or 
cathelicidin antimicrobial peptide (known as LL-37), can also inhibit the activity of the 
TcdB (see below) via a mechanism that involves direct binding to the toxin67. Innate 
lymphoid cells, specifically class 1, are implicated in resistance against C. difficile 
disease52. [Au:OK?] 
 
Resistance of the bacterium to host-produced antimicrobial compounds is 
multifactorial69 and mediated by, for example, the extracytoplasmic function (ECF) 
sigma factor CsfV70, the site-1 protease PrsW71, the proteins encoded by the cpr locus72 
and modulation of cell wall charge73.  
 
[H2] The large clostridial toxins TcdA and TcdB  
[H3] Regulation of expression. Although several virulence factors contribute to 
retention of the C. difficile within the gastrointestinal tract74,75, the symptoms of CDI 
correlate with the presence of a toxin-encoding pathogenicity locus (PaLoc) in the 
bacterial genome76,77. In most strains, the PaLoc is located at the same site in the 
chromosome77,78. The PaLoc in most pathogenic C. difficile strains encodes two large 
homologous toxins (TcdA and TcdB), and three proteins that seem to regulate toxin 
production and secretion (TcdR, TcdE and TcdC) (Figure 4A)74,75,78.  
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TcdR is a member of the ECF family of alternative sigma factors and is critical for the 
initiation of TcdA and TcdB production in C. difficile79,80. TcdC is thought to encode an 
anti-sigma factor that negatively regulates toxin production81. Epidemic ribotype 027 
strains carry a nonsense mutation within the tcdC gene, leading to the suggestion that 
derepression of the toxin genes by the inactivation of TcdC might contribute to the 
increased virulence of these strains82. However, despite many studies aimed at defining 
the role of TcdC in toxin production and virulence, conflicting findings have been 
reported and the functional role of this protein remains unclear75.  
 
TcdE has homology with bacteriophage holin proteins, which are involved in the release 
of progeny phages from infected bacterial cells83. The role of TcdE is also poorly 
understood, although some evidence suggests that it facilitates toxin (TcdA and TcdB) 
secretion78,84,85. TcdA and TcdB do not possess any recognizable signal or export 
sequences, suggesting that they might be exported from the bacterial cell by lysis or a 
non-classic secretion pathway, possibly involving TcdE84,85.  
 
The synthesis of TcdR and the subsequent activation of tcdA and tcdB expression is 
influenced by many environmental stimuli, including short-chain fatty acids such as 
butyric acid that are common in the gut and sub-inhibitory concentrations of certain 
antimicrobials that may be relevant in the context of disease79,86–89. Amino acids such as 
proline, cysteine and certain branched chain amino acids in the local environment of the 
bacterium repress toxin production through the action of the global transcriptional 
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regulator CodY (known as GTP-sensing transcriptional pleiotropic repressor CodY)90. The 
presence of glucose or other rapidly metabolizable carbon sources in the local 
environment of the bacterium also inhibits the production of TcdA and TcdB via the 
carbon catabolite control protein A (CcpA)91,92. The sigma factor SigD, which is 
associated with the expression of motility genes, promotes toxin gene expression by 
binding to a SigD-dependent promoter sequence upstream of tcdR93,94. The master 
regulator of sporulation in both Bacillus and Clostridium species, Spo0A, can also 
regulate toxin production in C. difficile, but only in some strains95. Specifically, Spo0A 
negatively regulates TcdA and TcdB production in epidemic type PCR ribotype 027 
strains but not in others that have been tested95–97. These results highlight the 
heterogeneous nature of C. difficile isolates and the need to study strains belonging to 
distinct evolutionary lineages95,98. Finally, growth signals and cell density play an 
important part in toxin regulation60,61. Cell–cell signalling is at least in part dependent on 
an accessory gene regulator quorum signalling system, which is mediated by a novel 
thiolactone quorum signalling peptide60,61. Overall, C. difficile toxin synthesis is closely 
connected to the metabolic state of the bacterium and its environment99. 
 
[H3] Mechanism of action. Structural and functional studies have provided insights into 
the mechanisms of action of all of the C. difficile toxins, particularly TcdA and TcdB. 
Once secreted, TcdA and TcdB bind and enter the colonic epithelium to cause 
inflammatory chemokine and cytokine production, an influx of neutrophils, disruption of 
tight junctions, fluid secretion, and epithelial cell death (Figures 5 and 6) 100. Given the 
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homology between the two proteins, it is notable that TcdA and TcdB have very 
different functions in animal toxicity models. Historically, TcdA has been viewed as the 
more potent enterotoxin, as administration of purified TcdA into the intestines of 
rabbits and rodents was shown to cause tissue necrosis and an intense infiltration of 
immune cells101–103. Higher levels of TcdB in identical experiments failed to induce these 
effects, although it should be noted that most of these studies were conducted in an 
ileal loop model and, accordingly, represent only the response of the small intestine. In 
studies involving human colonic tissue, TcdB seems to be a potent inflammatory 
toxin104,105; TcdA is weaker104 [Au:OK?]. These data suggest that the differential toxin 
responses might in part stem from differences in receptor tropism and highlight the 
importance of conducting mechanistic studies within the colon, which is the site of 
bacterial outgrowth in the host.  
 
TcdA and TcdB have four functional domains100,106: an N-terminal glucosyltransferase 
domain (GTD), an autoprotease domain (APD), a pore-forming and delivery domain and 
the CROPS domain, which extends from around residue 1,830 to the C-terminus (Figure 
5A and B). A combination of electron microscopy and X-ray crystallography studies has 
revealed the structural organization of these domains in TcdA and suggests that the 
structure of TcdB is similar106,107. TcdA and TcdB enter cells via receptor-mediated 
endocytosis108. Historically, receptor-binding has been associated with a combined 
repetitive oligopeptides (CROPS) domain located at the C-terminal ends of TcdA and 
TcdB109. The CROPS domain is capable of binding carbohydrates, which is consistent 
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with the model wherein TcdA engages glycosylated receptors110. Evidence supporting 
the idea that the TcdA CROPS contributes to receptor binding includes the observations 
that antibodies against the TcdA CROPS domain can block intoxication111, and that 
excess TcdA CROPS domain can compete with TcdA holotoxin for cell binding112. TcdA 
binds a variety of carbohydrates, and while multiple glycolipids and glycosylated 
proteins have been proposed as receptors109, the specific receptors used to bind human 
epithelial cells remain unknown. However, accumulating evidence suggests that 
domains other than CROPS participate in receptor binding. Indeed, TcdA and TcdB toxins 
lacking CROPS domains are still capable of intoxicating cells113,114, and the homologous 
TpeL toxin from C. perfringens lacks a CROPS domain entirely115. Recently, two protein 
receptors have been reported for TcdB: poliovirus receptor-like protein 3 (PVRL3, also 
called nectin 3)116 and chondroitin sulfate proteoglycan 4 (CSPG4)117. PVRL3 is highly 
expressed on the surface of human colon epithelial cells and co-localizes with TcdB in 
tissue resected from a C. difficile-infected individual116, suggesting that PVRL3 could 
serve as the initial receptor that TcdB encounters in the context of infection. CSPG4 is 
highly expressed in the intestinal subepithelial myofibroblasts of mouse and human 
intestines118, suggesting that this receptor could be engaged after initial damage to the 
colonic epithelium117. Both CSPG4 and PVRL3 bind outside the CROPS domain116,117. It is 
conceivable that additional alternative receptors for TcdB exist. 
 
Following receptor binding and endocytosis, acidification of the endosome is thought to 
trigger a structural change in the delivery domain, allowing for pore formation and 
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translocation of the GTD into the cytosol (Figure 5C)109. The APDs share sequence 
homology with the cysteine protease of the MARTX family of toxins119,120, but one 
publication has shown that the catalytic dyad of TcdA and TcdB serves to coordinate a 
zinc ion that is essential for function106. Activation of the APD by eukaryotic inositol 
hexakisphosphate (InsP6) results in the release of the GTD into the cell, enabling access 
to cytosolic substrates119,120. Host S-nitrosylation at the conserved cysteine of the APD 
can inactivate the protease activity in an InsP6-dependent manner121. It has been 
hypothesized that the autoprotease and translocation efficiency contribute to the 
increase in virulence of the epidemic PCR ribotype 027 strain122. The GTD transfers 
glucose from UDP-glucose onto Rho family GTPases such as Rho, Rac1, and Cdc42 
(Refs123,124). These modifications cause a cytopathic effect resulting from rearrangement 
of the actin cytoskeleton and can lead to apoptosis125 (Figure 5C). At higher 
concentrations, TcdB is also capable of coordinating the assembly of the NADPH oxidase 
complex on endosomes126. The resulting production of reactive oxygen species (ROS) 
leads to cell death by a necrotic mechanism126 (Figure 5D). Both mechanisms might be 
important in the context of disease; cytopathic effects promote inflammation and 
disruption of the tight junctions, whereas TcdB-induced necrosis contributes to the 
colonic tissue damage observed in severe cases of CDI.  
 
Knowledge of the toxin mechanisms of action has served as a foundation for several 
pre-clinical studies aimed at the identification of small-molecule inhibitors of 
intoxication, especially those that are already approved for other uses127. A recent 
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screen for inhibitors of TcdB cytopathic effects revealed compounds that act by 
inhibiting toxin binding to cells, endosomal maturation or glucosyltransferase 
function128. Another screen, conducted using an activity-based probe for inhibitors of 
the APD, identified ebselen, a US Food and Drug Administration (FDA)-approved 
compound, which reduced tissue pathology in a mouse infection model129. Of note, 
ebselen has also been reported to block NADPH oxidase 1 activity130, a function that 
could contribute to a decrease in toxin-induced ROS. Similarly, N-acetylcysteine, an FDA-
approved antioxidant, has been shown to prevent TcdB-induced tissue damage in a 
colonic explant model126.  
 
[H3] Pathology. Although the roles of TcdA and TcdB in the context of CDI have been 
difficult to assess, recent progress has come through advances in the genetic 
manipulation of C. difficile. Four studies have been conducted in both hamster and 
mouse models of infection. All studies indicate that TcdB is capable of inducing the 
phenotypes of disease in the absence of TcdA, but differ on the interpretation of the 
role of TcdA in the absence of TcdB on survival of animals2,3,131,132. Histological 
examination of colonic and caecal tissue from mice infected with TcdB-positive C. 
difficile strains (either wild type TcdA+/TcdB+ or TcdA-/TcdB+ mutants) showed severe 
gut damage associated with eroded and often absent crypts, mucosal ulceration and 
goblet cell loss132. Polymorphonuclear cell (PMN) influx into the lamina propria, 
enterocyte hyperplasia and severe submucosal oedema associated with haemorrhage 
was also observed in these tissues. TcdB-negative strains (TcdA+/TcdB-) caused less 
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tissue damage that was confined to mild oedema and PMN influx132. Tissue damage was 
strictly dependent on TcdB or TcdA given that tissues from mice infected with a strain 
that did not produce TcdA or TcdB (TcdA-/TcdB-) resembled those of mock-infected 
control animals (Figure 6)132.  
 
Consistent with the finding that TcdB is independently capable of causing disease, a 
considerable number of clinical C. difficile isolates only express TcdB133. The prevalence 
of these strains, which include PCR ribotype 017, has been increasing, sometimes to 
epidemic proportions134. Recently the first strain with an intact tcdA gene, but no tcdB 
gene, in a different genomic context than the PaLoc has been characterized78. This work 
has raised the hypothesis that the single toxin-encoding loci might have fused to form 
the typical two-toxin locus (PaLoc), which is the most common form currently detected 
in clinical isolates. The study also suggests a conserved relationship between the 
presence of toxin genes and holin genes, and demonstrates that the PaLoc does not 
always encode a tcdC homolog78. However, it should be noted that confirmed clinical 
cases of CDI caused by strains that only produce TcdA are extremely limited78.  
 
[H2] Binary toxin CDT 
[H3] Regulation of expression. C. difficile transferase (CDT; or binary toxin) is a third 
toxin produced by some C. difficile strains, including the epidemic PCR ribotypes 027 and 
078. CDT has received attention in recent years because of its increasing prevalence in 
isolates of both human and animal origin135. CDT is encoded by two genes, cdtA and 
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cdtB, that are located in an operon on the CdtLoc (Figure 3B)136,137. In binary toxin-
negative strains, this locus contains a ~2 kb deletion138. The CdtLoc also harbours a 
response regulator gene, cdtR, upstream of the cdtAB operon139. CdtR is an orphan 
LytTR-like positive transcriptional regulator of the cdt operon and CDT production. The 
cognate sensor histidine kinase that interacts with the orphan histidine kinase CdtR has 
yet to be identified139. A truncation in the C. difficile PCR ribotype 078 CdtR does not 
abrogate CDT expression, suggesting that full-length CdtR is not essential for 
expression140. Unlike the PaLoc, the environmental signals that regulate expression of 
the CdtLoc genes are not known. 
 
[H3] Mechanism of action. Recent studies have provided insights into the mechanisms 
of action of CDT, although the role of this toxin in disease pathogenesis remains unclear. 
CDT belongs to the binary ADP-ribosylating toxin family and comprises two components: 
the enzymatic component (CDTa) that has ADP ribosyltransferase activity and the 
binding/translocation component (CDTb) that facilitates the passage of the enzymatic 
component to the cell cytosol (Figure 7)135. CDTa ultimately leads to the complete 
destruction of the actin cytoskeleton and, ultimately, cell death135,141.  
 
[H3] Pathology. Despite a thorough understanding of the mechanism of action of CDT 
on intoxicated cells, the role of this toxin in disease pathogenesis is not clear. 
Experimental data has suggested that CDT results in the formation of microtubule-based 
protrusions on epithelial cells that might increase the adherence and colonization of C. 
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difficile142. Importantly, the increasing presence of CDT in clinically relevant strain types 
commonly associated with severe CDI, such as PCR ribotype 027 and 078, and the 
isolation of TcdA-/TcdB-/CDT+ strains suggest that this toxin is likely to play an important 
but as yet undefined part in CDI143,144.  
 
[H2] Experimental models 
Multiple experimental models have been developed as a proxy for CDI and its treatment 
in humans145–147. The most common models are the female Golden Syrian Hamster 
model, which is exquisitely sensitive to toxin and is primarily suited to study acute 
disease, and the mouse model. The mouse model mimics certain aspects of human 
disease that are difficult to assess in hamsters; for instance, mice can be colonized 
asymptomatically, there is differential sensitivity towards different PCR ribotypes and 
they can experience relapsing disease. For these reasons, the model is suitable to study 
colonization, transmission and persistence phenotypes38,148,149. A piglet model is of 
special interest to study C. difficile strains that are problematic in both animal and 
human populations13,35,150. In vitro gut models have been developed to study 
interactions of C. difficile with therapeutics in the context of a complex 
microbiome13,151,152. Each model is greatly influenced by variables such as qualitative 
and quantitative differences in inoculum and the choice of C. difficile strain147. Non-
animal models (for example, the in vitro gut models) additionally may not fully reflect 
the interaction with the host, but some have been shown to be more reflective of 
human CDI than animal models147.  
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[H1] Diagnosis, screening and prevention  
[H2] Symptoms and risk factors 
The clinical symptoms associated with CDI range from mild, self-limiting diarrhoea to 
fulminant colitis and can include pseudomembranous colitis (Figure 1D), toxic 
megacolon (severe dilatation of the colon), bowel perforation and sepsis, and/or 
multiple organ dysfunction syndrome14,132,153. Given the characteristics of patients who 
can acquire CDI are highly variable, there is considerable variation in the possible 
severity assessments for this disease, which is reflected in the differing criteria used in 
guidelines154,155. Severe diarrhoea associated with C. difficile is often accompanied by a 
typical endoscopic picture of pseudomembranous colitis with haemorrhage and deep 
ulcerations. Toxin megacolon is considered the most serious disease entity and is 
characterized by systemic toxicity and high mortality. Extra-intestinal manifestations of 
CDI (including bacteraemia) are extremely rare, which emphasizes that it is the localized 
effects of toxins, associated with depleted intestinal microbiota, that cause the range of 
signs and symptoms of CDI. C. difficile toxins in sera from patients with CDI can be 
detected with an ultrasensitive cell-based assay156, but studies are required to assess 
the relationship between severe CDI and levels of toxaemia.  
 
Known risk factors are previous hospitalization, underlying disease, advanced age (>65 
years), and most importantly, the use of antibiotics. All antibiotic classes can be 
associated with CDI, but clindamycin, cephalosporins and fluoroquinolones are most 
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frequently cited157. Antibiotic-induced dysbiosis of the protective intestinal microbiota 
often underlies C. difficile outgrowth and toxin production39,43. Thus, even low-risk 
antibiotics (such as trimethoprim and piperacillin-tazobactam) can predispose the 
patient to CDI, especially when two or more courses of (different) antibiotics are 
prescribed; the cumulative damage to the intestinal microbiota could be sufficient to 
enable C. difficile to proliferate.  
 
Besides the antibiotic class, the number of administered antibiotics, dose and duration 
of therapy have been identified as risk factors for CDI. Given that disruption of the 
intestinal flora persists for >3 months after antibiotic therapy, patients can remain 
susceptible to CDI development long after ending the treatment28. Acid suppression by 
proton pump inhibitors (PPIs; commonly used for dyspepsia, peptic ulcer disease and 
gastroesophageal reflux disease) has frequently been associated with CDI158,159 but the 
precise role (and a causal relationship) of PPIs in CDI remains unclear160,161. Of all 
patients with antibiotic-associated diarrhoea, 20–30% is caused by C. difficile162. A 
differential diagnosis could consider a role for Staphylococcus aureus, C. perfringens, C. 
sordellii or Klebsiella oxytoca as causative agents of antibiotic-associated diarrhoea163. 
 
[H2] Diagnosis 
The mainstay for diagnosing CDI is the presence of clinical symptoms plus a well-chosen 
laboratory assay. The diagnostic tests for C. difficile can be divided into tests for C. 
difficile products (glutamate dehydrogenase (GDH), aromatic fatty acids, TcdA and/or 
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TcdB); culture methods for the detection of toxin-producing C. difficile (toxigenic 
culture); and nucleic acid amplification tests for C. difficile genes (detecting 16S rRNA, 
toxin genes or the gene encoding GDH)162. The test selection is important to 
differentiate between patients with CDI and asymptomatic carriers34,164. Tests that 
detect toxin are specific to CDI, whereas those that detect (a component of) the 
bacterium could indicate colonization rather than disease34,164. 
 
Exclusive reliance on molecular tests for CDI diagnosis without tests for toxins likely 
results in over-diagnosis and over-treatment34,165. Due to large variations of sensitivity 
and specificity of various diagnostic tests, the European Society of Clinical Microbiology 
and Infectious Diseases recommends using a two-step algorithm, including a test for the 
presence of C. difficile and one to detect free toxins in the faeces166. Since tests remain 
positive for toxin during treatment and can even be found after successful treatment167, 
regular monitoring using toxin tests as follow up for treatment is not advised. If free 
toxins are absent, CDI is highly unlikely (Figure 8). Importantly, C. difficile toxin assays 
vary markedly in their sensitivity34,164,168. If C. difficile is present but the toxin test result 
is negative, CDI cannot be definitively excluded. Patients could be either 
(asymptomatically) colonized by C. difficile with diarrhoea owing to an alternative cause, 
or experience CDI with toxin levels below the lower limit of detection of the assay used. 
For these patients, clinical evaluation is required to decide if treatment for CDI is 
warranted.  
 
 Smits et al 23 
 
An alternative diagnostic algorithm uses a coupled enzyme immune assay that 
simultaneously detects both GDH and TcdA/B169. As the sensitivity of the toxin 
component is unclear; samples that are GDH-positive but toxin-negative could undergo 
reflex testing using a nucleic acid amplification test to determine if a toxigenic C. difficile 
strain is present. Ideally, every laboratory should also have the opportunity to isolate C. 
difficile from faecal samples. Isolation enables toxigenic culture and susceptibility 
testing, and offers the ability to perform molecular typing that is required for 
surveillance (Box 1). Many countries have implemented reference laboratories for this 
purpose33. The most recent US (the Society for Healthcare Epidemiology of America and 
the Infectious Diseases Society of America) guidelines on testing were published in 2010 
and did not make a firm recommendation regarding the routine diagnosis of CDI154. 
 
[H2] Screening 
There is a great variation between and within countries in the diagnostic algorithm 
applied but also the frequency of testing (when to test). A study involving almost 500 
hospitals in 20 countries across Europe revealed that 23% of diarrhoeal samples with a 
positive CDI test result (at a reference laboratory) were initially missed owing to lack of 
clinical suspicion32. Hence, restricting testing of samples to those for which a physician 
has request for CDI testing will lead to under-diagnosis. All stool samples from 
hospitalized patients with diarrhoea should be tested unless a plausible alternative 
explanation (such as laxative use or diagnosis of inflammatory bowel disease) is 
available155,164,170, or if the patient is <2 years of age. Indeed, C. difficile is commonly 
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found in the faeces of healthy infants, and there is no general agreement on how to 
define CDI in children or when to test for CDI in children, especially with respect to age, 
underlying disease and use of antibiotics1,171. However, CDI can occasionally occur in 
infants and young children, and can cause microscopic intestinal lesions with symptoms 
other than diarrhoea. The American Academy of Pediatrics has recently recommended 
testing for CDI only if age-specific clinical criteria are met172.  
 
As C. difficile is increasingly recognized as a causative agent of community-associated 
diarrhoea, one can consider testing all diarrhoeal samples from community patients but 
it can be cost-prohibitive to test a large number of samples. Application of specific 
algorithms, such as testing those with diarrhoea who have previously been hospitalized 
or used antibiotics, results in recognition of only 61% of patients with CDI in the 
community28. The introduction of multiplex molecular tests for enteric pathogens makes 
it easier to implement routine testing (screening) for CDI, although positive tests of C. 
difficile should be followed by a stool toxin detection test (two-step algorithm). In a 
European, multicentre, quarterly point-prevalence study of community-acquired 
diarrhoea applying molecular tests, C. difficile was found among 709 samples as the 
third most frequently occurring pathogen, after enteropathogenic Escherichia coli and 
Campylobacter sp.173 In that study, children were also included (potentially identifying 
colonized rather than infected individuals) and a large variation per country was 
observed173. C. difficile occurred more frequently in the >60-year age group than in 
other age groups. Application of molecular diagnostics in a case–control study of 
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patients with diarrhoea attending a general practitioner in the Netherlands revealed 
that C. difficile was found in 4.2% of 1,515 cases and 0.8% of 1,195 healthy controls174. 
This is considerably higher than the prevalence of Salmonella sp. and Shigella sp. and 
confirmed that C. difficile is frequent in general practice24.  
  
[H2] Asymptomatic carriage 
For both healthcare and community-associated infection, it is necessary to differentiate 
between colonization and disease34,164,165. Carriage and colonization are often deemed 
as interchangeable terms175,176. Indeed, the criteria used to determine asymptomatic 
carriage and/or colonization vary markedly between studies. A clarification of 
terminology is required, as a single C. difficile-positive faecal sample could indicate 
anything from colonization, transient carriage or ‘pass-through’177. We prefer to use the 
term ‘carriage’ to refer to persistent ‘colonization’.  
 
Most studies use just one single culture and, therefore, evaluate passage or transient 
colonization, here defined as asymptomatic colonization. Asymptomatic C. difficile 
colonization is common in healthcare facilities and in the community, and can be 
attributable to toxin-positive or toxin-negative strains36,178–180. In hospitals, the 
prevalence of asymptomatic colonization varies from 7–18%, dependent on the length 
of stay, exposure to antibiotics and to C. difficile (infection pressure), underlying disease 
and possibly use of acid-suppressive medication. Indeed, the environment is most 
contaminated in rooms of patients with CDI, less so in rooms of patients 
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asymptomatically colonized with C. difficile and least in patients who are not 
colonized181. During outbreaks, colonization rates may further increase to >50%179. 
Asymptomatic colonization in the community is lower than in the healthcare setting and 
is in the range of 2–4%. Several studies report on high carriage rates (25-35%) in 
children in the first year; the rate drops (to 15%) between the ages of 1–8 years182–184. 
This variation is probably associated with the unstable intestinal microbiota in the first 
2–3 years of life, which enables C. difficile to remain established in the intestinal tract185. 
Interestingly, high levels of free toxin can also be detected in faecal samples of young 
children without diarrhoeal symptoms — further reinforcing the need for information 
on the effects of toxins on intestinal epithelial cells in children. 
 
Asymptomatic colonization has been considered a protective factor against the 
acquisition of new C. difficile isolates. A frequently cited meta-analysis of four studies 
from 1994 showed that patients colonized with C. difficile actually had a lower risk of 
subsequently developing CDI, but no distinction was made between colonization by 
toxigenic versus non-toxigenic strains186. A recent meta-analysis included studies in 
which patients were colonized with toxigenic strains at hospital admission only36. It 
should be noted that in this study, unlike the previous186, patients with previous CDI 
were not excluded and so could have confounded the results. Overall, the colonized 
patients had an increased risk of developing CDI (relative risk 5.86; 95% CI: 4.21–8.16). 
By contrast, patients asymptomatically colonized by non-toxigenic strains do not seem 
to have an increased risk or are even protected from progressing to CDI. This concept 
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was recently tested in humans; patients who could be colonized by a non-toxigenic C. 
difficile strain after receiving standard of care treatment for CDI had significantly 
reduced CDI recurrence rates187. However, further explorations of this approach should 
consider that non-toxinogenic strains can become toxinogenic by horizontal gene 
transfer188, though it is unknown if this also occurs in a human host. 
 
Asymptomatically colonized patients can shed spores into their environment and 
subsequently to other patients. As early as 1992 it was recognized that nosocomial 
acquisition of a C. difficile strain was preceded by introduction of that strain to the ward 
by an asymptomatically colonized patient189. On the basis of an epidemiological model 
of C. difficile transmission in healthcare settings, admission of colonized patients was 
shown to plays an important part in sustaining ward-based transmission190. This 




[H2] Infection control 
Several reviews and guidelines for control of CDI have been published154,155,157,191–195. 
Although some differences exist, most of these guidelines have similar 
recommendations (Box 3). If a patient is suspected of having CDI, rapid diagnostic 
testing should be performed to enable treatment initiation as soon as possible. Spores 
are highly infectious and problematic in healthcare settings as they are able to persist 
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on surfaces and are resistant to many disinfectants and alcohol-based hand washes37. 
Up to 1×107 spores per gram of faeces are present in patients with CDI, representing a 
considerable potential for environmental contamination. Treatment should, therefore, 
always be combined with patient isolation to prevent spread of C. difficile or other 
enteropathogenic microorganisms.  
 
In a healthcare setting, transmission of C. difficile spores occurs mainly via the 
contaminated hands of healthcare workers, but contact with a contaminated 
environment, utensils or medical devices has also been implicated; C. difficile spores 
have been identified in rooms of patients who have tested negative. Environmental 
decontamination of clinical areas, ideally using chlorine-releasing agents or a sporicidal 
product, is recommended, but in practice compliance with cleaning protocols is often 
suboptimal154. Newer alternatives for environmental decontamination have been 
introduced, notably gaseous hydrogen peroxide and, more recently, UV 
decontamination196. The former is particular effective at killing C. difficile spores, but the 
cost-effectiveness of these approaches is unclear.  
 
[H2] Antimicrobial therapy and surgery 
The currently available antibiotics that are recommended for treatment of CDI are 
metronidazole, vancomycin and fidaxomicin (Figure 8). Stopping the inciting antibiotics 
and clinical observation can treat very mild CDI that has been induced by antibiotics155. 
Patients with mild-to-moderate CDI can be treated with oral metronidazole but oral 
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vancomycin is recommended for severe or complicated infections154,155,193. Two 
multinational randomized controlled trials included patients managed with either 
vancomycin or metronidazole197. Metronidazole was inferior to vancomycin on an 
intention to treat basis (clinical cure rates 72.7% versus 81.1%). Also, in a post-hoc 
multivariate analysis, vancomycin, treatment-naive status and mild-to-moderate CDI 
severity predicted treatment success. 
 
Concomitant antibiotics are associated with reduced clinical cure, increased recurrence 
rates, and longer time to cessation of diarrhoea198. Additional measures to curb CDI, 
therefore, include discontinuation of unnecessary antimicrobial therapy (that is, for the 
presenting infection), as well as avoidance of anti-motility medications and reviewing 
PPI use155. Patients with complicated CDI with ileus (paralysed bowel) or toxic 
megacolon, in whom oral antibiotics cannot reach the disease site, can be treated with 
vancomycin delivered per rectum plus intravenous metronidazole.  
 
Fulminant CDI is a highly lethal disease with mortality rates of up to 80%. These patients 
often require a total abdominal colectomy, but there is no established management 
protocol. Alternatively, a diverting loop ileostomy and colonic lavage might be 
associated with reduced morbidity and mortality199. Surgical therapy should be 
considered in patients with toxic megacolon, clinical signs of sepsis and severe organ 
dysfunction, acute abdomen and severe ileus. A white blood cell count ≥15,000–
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20,000/μl and elevated serum lactate (>5.0 mM) might serve as markers for 
severity154,155,200.  
 
[H2] Recurrent infection 
After treatment of an initial episode of CDI, the chance of a recurrence within 8 weeks is 
15–25%; for a patient with 1–2 previous recurrences, the risk of further recurrences is 
40–65%201. Recurrences are associated with an impaired immune response to C. difficile 
toxins and/or alteration of the colonic microbiota. Fewer recurrences occur after 
treatment with oral fidaxomicin (13%) than with vancomycin (25%)202,203. However, 
after a first recurrence, optimal treatment options are less clear, but fidaxomicin might 
be effective198,202,203. Despite these shortcomings, fidaxomicin is generally used for 
treating a first recurrence of CDI, unless disease has progressed from non-severe to 
severe (Figure 8). Given that the main strength of fidaxomicin is prevention of recurrent 
infections (except for those due to PCR ribotype 027 that generally respond less well to 
antibiotics), clinical prediction markers for recognizing patients at risk for recurrent CDI 
could be helpful. Multiple risk factors for recurrent CDI have been suggested in the 
literature, but as not all of these are evident at the time of treatment initiation, it is 
difficult to select appropriate parameters. Age >65 years, concomitant antibiotics, renal 
failure, history of previous CDI, possibly continued use of antacid medications and initial 
disease severity155,204 are associated with increased risk of recurrence.  
 
[H2] Bacteriotherapy and faecal microbiota transplantation 
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Limited evidence supports the use of probiotics to decrease recurrences of CDI, and no 
effective immunotherapy is currently available205. Faecal microbiota transplantation 
(FMT) is a very effective rescue treatment and should be considered in patients who 
have had >2 recurrences, as the efficacy of antibiotics in those patients is ~30%. A 
randomized controlled trial of FMT revealed that it is highly effective (~81%) in treating 
multiple recurrent CDI (Figure 9)206. FMT is best reserved for patients with multiple 
recurrences of CDI that have failed other treatment options. Importantly, FMT is a non-
standardized procedure, and the long-term consequences of altering a patient’s gut 
microbiota are unknown. Several national guidelines have, therefore, been developed to 
standardize FMT including donor screening and selection207–209. Results from a 
preliminary study among patients with relapsing CDI revealed that administration of 
FMT using frozen encapsulated inoculum from unrelated donors also resulted in a good 
outcome210. It is likely that future research will define mixtures of selected microbes, 
designed according to their roles in the microbiota against CDI, as ‘pharmacological’ 
alternatives to FMT. For example, a mixture of 33 bacteria has been shown to be 
effective in two patients with CDI211, although the selection of the isolates here was not 
based on microbiota studies. Rectal bacteriotherapy with a mixture of 12 bacteria from 
healthy donors [Au:OK?] resolved CDI and prevented recurrence within 30 days in 64% 
of the patients212. A combination of four bacterial species selected on the strongest 
association with resistance to CDI, protected mice from infection, most likely indirectly 
by an effect on the bile acids metabolism42. As noted for FMT, long term safety data will 
be needed, given the far-reaching effects of gut microbiota in health and disease.  
 Smits et al 32 
 
 
[H2] Novel therapeutics 
Several therapeutics targeting different stages of CDI are currently in clinical 
development (Table 1). In short, these comprise treatments to restore a complex 
microbiota (SER-109)213, to prevent off-target effects of antibiotic treatment on the 
intestinal microbiota (SYN-004), to neutralize C. difficile toxins (including monoclonal 
antibodies)214, or to inhibit C. difficile proliferation (SMT19969, LFF571, surotomycin, 
cadazolid, PolyCAb, CRS3123). 
 
[H1] Quality of life 
[H2] Economic burden of CDI 
The burden of healthcare-associated CDI can be expressed in terms of mortality, 
recurrence, (additional) length of hospital stay or economic cost215–217. Economic 
analyses of healthcare-associated CDI have shown that direct healthcare cost and costs 
due to increased length of stay were the main cost drivers. An integrative review 
showed a wide variation in the difference in length of stay between people with and 
those without CDI (2.8–16.1 days), which was attributed to differences in design and 
data collection218. However, overall, people with CDI stay longer in hospital than people 
without CDI despite this variation.  
A systematic review of the effects of CDI in Europe showed that the median length of 
stay for patients with CDI was in the range of 8–27 days, with an additional length of 
stay (due to CDI) between 2.8–18 days217. The incremental per-case cost of CDI in this 
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study was £4,577 in Ireland and £8,843 in Germany, after standardization to 2010 
prices217. Others have estimated the incremental per-case cost of CDI, after 
standardization to 2008 prices, at US$2,871–90,644 (Refs 216,219) (Figure 10). A recent 
meta-analysis identified a total of 45 studies (mostly from North America) that 
measured the economic impact of CDI. For hospitalized patients, attributable mean CDI 
costs ranged from $8,911 to $30,049. However, the authors noted that costing methods 
were heterogeneous, making inter-study and setting comparisons difficult. 
Standardization of such measurements would be helpful, although differences between 
healthcare systems remain a barrier when comparing financial costs220. 
 
The total direct cost of CDI to the European Union in 2006 was estimated at €3 billion 
per year6. Assuming a 3% annual inflation rate, this approximates to over €4 billion in 
2015. Estimates for the economic burden of CDI in the United States and Canada are in 
excess of US$1 billion221 and CAN$280 million222, respectively. These figures do not 
include the indirect socioeconomic costs (see below). Only for Canada does the estimate 
includes a parameter for community-associated CDI in addition to healthcare associated 
CDI222; so, the total burden in the United States and European Union probably exceeds 
the numbers given above. 
 
[H2] Patient-reported quality of life 
The stark mortality rates associated with CDI emphasize the serious consequences of 
this disease. Furthermore, given that CDI is characterized by diarrhoea, relatively 
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frequent symptomatic recurrences, and often altered bowel habit for possibly weeks or 
months following cessation of acute symptoms, it is perhaps not surprising that patients 
regularly report that this disease is one of the worst they have experienced223. As 
patients are typically older and have comorbidities, the additional burden of CDI can 
affect both their dignity and ability to cope. Despite these well-recognized effects of CDI, 
very few data are available to formally measure how the disease affects an individual’s 
health status, functionality and quality of life. Two recent studies have begun to explore 
these under-reported issues.  
 
A prospective study of 66 out-patients with CDI used the RAND Short-Form 36 (SF-36) 
Health Survey and concluded that CDI significantly decreased overall quality of life but 
that a more-specific health-related questionnaire is needed. The Patient-Reported 
Outcome Measurement Information System (PROMIS) is a large, NIH-funded, database 
of questions to measure patient-reported health status for physical, mental and social 
well-being224. PROMIS has recently been explored in a prospective, observational, multi-
centre study as a potential way of evaluating self-reported health status in patients with 
CDI225. Patients (n=95) with active CDI (58%) or who were hospitalized (42%) had worse 
scores in regards to bowel function, nausea, and belly pain compared with controls (P 
<0.001). Those with recurrent CDI had worse anxiety scores than any other group 
(patients with first-occurrence of CDI and controls; P <0.001). The authors concluded 
that the 18 patient-reported health status questions were discriminatory for active CDI 
and primary versus recurrent CDI. These questions might be suitable for measuring 
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short-term and long-term differences in patient-reported health status in people with 
CDI. 
 
CDI can also have long lasting effects on families, but there is no systematic evaluation 
of these effects.  
More work is needed to optimize these measurements and to determine which 
interventions are associated with the best improvements in outcomes for both patients 
and relatives. 
 
[H1] Outlook  
[H2] Outstanding research questions  
Great progress has been made in our understanding of C. difficile physiology and 
pathogenesis. Studies have not only provided insight in the workings of the pathogen, 
but also highlighted aspects of its biology that differ from the situation in other studied 
bacteria. For instance, the order, activation and function of sporulation sigma factors of 
C. difficile deviates from what is known for the best studied Gram-positive spore former, 
Bacillus subtilis226. Perhaps this should not come as a surprise, as the last common 
ancestor of bacilli and clostridia dates back about 2.7 billion years, only shortly after the 
divergence of Gram-positive and Gram-negative bacteria (3.2 billion years ago)227. It is 
conceivable that more-detailed investigations of the molecular biology of clostridia in 
general, and C. difficile in particular, will reveal unexpected features. 
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Laboratory investigations under controlled conditions have clearly demonstrated that 
the production of enterotoxins is regulated in a complex manner and integrates signals 
from both the bacterial metabolism as well as the culture conditions99. It is uncertain, 
however, whether this reflects infection within in the host. Mutants that are used to 
assess these effects in the laboratory might display reduced virulence as a result of 
reduced fitness. Although the role of enterotoxins in disease is well established, it 
remains unknown how toxin production is triggered in vivo, and how or when the toxins 
are secreted into the gastrointestinal tract. Similarly, it is unknown what triggers 
sporulation during infection. Both toxins (production and activity) and spores have been 
implicated in epidemicity82,122,228. However, strong evidence for this is lacking and the 
ability of C. difficile to cause epidemics is likely a multifactorial process that involves a 
delicate balance in factors that affect virulence and transmissibility74,75. It should be 
noted that increased virulence might not correlate with transmissibility, which might be 
favoured when hosts remain relatively healthy75. 
 
Epidemic types of C. difficile have received a lot of attention as a result of their higher 
mortality and morbidity7,8,12,18,82. Often, enhanced infection control measures are taken 
when transmission of epidemic C. difficile types are detected, which has likely 
contributed to the decline of PCR ribotype 027 in different countries in 201432. But is the 
increased vigilance towards these strains warranted? First, epidemiological analyses 
ignore the fact that not all strains of the same PCR ribotype exhibit the same 
characteristics as has been demonstrated for sporulation229. Second, other PCR 
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ribotypes can also cause outbreaks of CDI20,21,230. Third, with the advent of sequence 
based typing methods, it is becoming clear that strains with different PCR ribotypes can 
be highly related98,231. For instance, strains of PCR ribotypes 244 and 176, which are 
related to PCR ribotype 027, can cause outbreaks of severe CDI22,23. PCR ribotype 244 
seems to be primarily implicated in community-associated CDI, indicating that highly 
related strains might emerge as epidemic types in different settings232. Finally, new 
types could emerge. Thus, care should be taken to not generate an unjustified bias 
towards certain strains in epidemiological vigilance. 
 
[H2] Colonization and pathogenesis 
What determines whether C. difficile successfully establishes an infection is an 
important question. The host microbiota and its associated metabolites greatly 
influence the ability of C. difficile spores to germinate and colonize the gut39,43. 
However, niche-specific competition233, or collaboration (for instance, in a multi-species 
biofilm57,59) might also contribute. Most of the metagenomic studies have focused on 
bacterial species whereas the contribution of fungal species and viruses 
(bacteriophages) is poorly explored. Notably, population groups with relatively unstable 
microbiomes (that is, infants185 and the elderly234) are most commonly colonized by C. 
difficile.  
 
Other host factors might also play a part. Failure to mount a protective immune 
response is associated with disease progression; patients with an adequate response 
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could either eliminate the infection, or become asymptomatic carriers14. Host-
dependent expression levels of toxin or colonization factor receptors could also be an 
important determinant for disease development. It has been postulated that infants 
remain asymptomatic in the presence of high levels of toxins due to the absence of 
receptors in their still-developing gastrointestinal tract, but so far there is no evidence 
to support this hypothesis. Detailed studies on the interaction of C. difficile with the host 
are necessary to delineate the contribution of host factors to colonization and 
pathogenesis. 
 
[H2] Clinical needs 
Even though antimicrobial resistance of C. difficile is not a major issue in the clinic, novel 
narrow-spectrum therapeutics are needed. The primary reason is that current (broad 
spectrum) antibiotics with activity against C. difficile, such as metronidazole and 
vancomycin, can concurrently predispose patients to CDI (and possibly recurrent CDI) 
due to their effects on other microbiota235. [Au:OK?] Furthermore, some antibiotics are 
not cost-effective as first-line treatment options. It is possible that specific prophylactic 
elimination of C. difficile in high-risk groups could reduce the risk of CDI without altering 
the host microbiome. It is of interest that bacteriocins and viruses (bacteriophages) 
seem to be able to target C. difficile specifically233,236,237.  
 
FMT is an excellent potential alternative for antibiotic therapy206, but long-term safety, 
public acceptance and relative lack of standardized donor material are limiting broad 
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application. Steps have been taken to generate standardized formulations of FMT or 
bacteria42,149,211,212. However, it remains to be established whether a single species of 
bacteria or mixtures of different bacteria are effective for all (or most) patients. It is 
likely that bacterial or metabolic signatures need to be identified that confer broad 
protection or activity against CDI (Figure 9).  
 
Anti-virulence strategies238 might become a valuable addition or alternative to the 
current therapeutic spectrum. Neutralizing anti-toxin antibodies have shown clinical 
promise (Table 1)214,239, and toxin activity has also been targeted using small 
molecules128,129. Interference with quorum sensing or colonization factors has been 
underexplored so far, though it is clear that these can also be targeted by 
antibodies240,241. Small molecule inhibition of extracellular protein processing or 
function could prove a viable strategy to reduce colonization or transmission of CDI. 
 
A final issue is the clinical need for accurate prediction models155. Accurate risk 
assessment tools that can be applied in real time would be beneficial to target 
diagnostic methods and for optimized treatment of those at risk of severe or 
complicated CDI or recurrence242–245. Though several tools have been developed, there 
is considerable room for simplification and improvements in predictive values to make 
these applicable at the bedside. 
 
[H2] The burden of CDI 
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Current conservative estimates of the economic burden of CDI are based on estimates 
of incidence and an incremental — per (hospitalized) patient — cost. These estimates 
fail to take into account the changes in demographics that are projected over the 
upcoming years. Age is a risk factor for CDI, though it is unclear if this is an independent 
factor or caused by underlying confounders (such as immune senescence, comorbidities, 
need to stay at long term care facilities and additional required health care). The 
European Union has projected that the demographic old-age dependency ratio (the 
ratio of those aged >65 years old to those aged 15–64 years) will increase from 27.8% to 
50.1% between 2013 and 2060 (Ref. 246). Similarly, US-based population projections 
foresee an increase in the percentage of people aged >65 years of 13.7% to 20.9% 
between 2012 and 2050 (Ref. 247). On the basis of these projections, the impact of CDI is 
expected to become considerable in coming years. 
 
Epidemiological evidence suggests that an increasing number of cases of CDI are linked 
to populations that are generally considered to be at low risk for CDI. These community-
associated infections generally affect a different demographic (younger patients) who 
have frequently not been exposed to antibiotics. Further studies are required to 
determine risk factors for community-associated CDI. As many cases of community 
acquired CDI go undetected24,27,29, more studies are required to determine the 
contribution to the total burden of CDI at a national and international level.  
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Finally, C. difficile is increasingly recognized in veterinary medicine with highly variable 
disease entities in different species of animals. No information is available to date on 
the economic burden of CDI in food (animal) production industry.  
 
Acknowledgements  
This work was supported, in part, by a Vidi fellowship from the Netherlands 
Organization for Scientific Research and a Gisela Thier Fellowship from the Leiden 
University Medical Center to W.K.S., National Institute of Health Award AI95755 and a 
Burroughs Wellcome Investigator in the Pathogenesis of Infectious Disease Award to 
D.B.L., and a Future Fellowship FT120100779 of the Australian Research Council to D.L. 
The authors thank the ESCMID Study Group for Clostridium difficile (ESGCD) for their 
advice and suggestions and apologize to authors whose work could not be cited due to 
restrictions imposed by the format of this Primer. W. Knetsch is acknowledged for 
drafting the illustration used in Box 1. 
 
Author contributions 
Introduction (W.K.S.); Epidemiology (M.H.W., E.J.K. and W.K.S.); 
Mechanisms/pathophysiology (D.B.L., D.L. and W.K.S.); Diagnosis, screening, and 
prevention (M.H.W., E.J.K. and W.K.S.); Management (M.H.W., E.J.K. and W.K.S.); 
Quality of life (M.H.W., E.J.K. and W.K.S.); Outlook (W.K.S. and E.J.K.); overview of the 
Primer (W.K.S.). 
 
 Smits et al 42 
 
Competing interests 
W.K.S. has performed research for Cubist. D.L. has performed research for Immuron and 
Adenium Biotech. D.B.L. has performed research for MedImmune and Merck. M.H.W. 
has received consulting fees from Abbott Laboratories, Actelion, Astellas, AstraZeneca, 
Bayer, Cerexa, Cubist, Durata, The European Tissue Symposium, The Medicines 
Company, MedImmune, Merck, Motif Biosciences, Nabriva, Optimer, Paratek, Pfizer, 
Roche, Sanofi-Pasteur, Seres, Summit, and Synthetic Biologics; has received lecture fees 
from Abbott, Alere, Astellas, Astra-Zeneca, Pfizer & Roche; and received grant support 
from Abbott, Actelion, Astellas, bioMerieux, Cubist, Da Volterra, The European Tissue 
Symposium, Merck and Summit. E.J.K. has performed research for Cubist, Novartis and 
Qiagen; and has participated in advisory forums of Astellas, Optimer, Actelion, Pfizer, 
Sanofi-Pasteur and Seres. These companies had no role in the writing of this Primer.  
 
 Smits et al 43 
 
Box 1. Molecular typing of Clostridium difficile  
Epidemiological studies are dependent on standardized typing methods. Many different 
typing methods have been developed for C. difficile that evaluate either phenotypic or 
genotypic traits17 (illustration). Given their higher reproducibility, typability (ability to 
type a strain unambiguously) and discriminatory power, genotyping methods have 
become standard for typing of C. difficile. Band-based typing methods, such as 
restriction enzyme analysis (REA), pulsed-field gel electrophoresis (PFGE), and PCR 
ribotyping (RT), are common. Historically, REA and PFGE have been the methods of 
choice in North America, whereas PCR ribotyping has primarily been used in Europe. As 
a result, epidemic strains are often indicated with multiple typing designations248. For 
instance, PCR ribotype 027 strains that have caused outbreaks globally8 have been 
classified as REA group BI and PFGE type NAP1. Similarly, PCR ribotype 078 strains are 
known as REA group BK and PFGE type NAP7/NAP8. Global surveillance is becoming key 
for health care management, and efforts have been made to harmonize the different 
typing schemes. Capillary gel-based electrophoresis ribotyping (CE-RT) has been 
standardized and validated in a collaborative effort of the European Centre for Disease 
Control and Prevention, the US Centers for Disease Control and Prevention and the 
Public Health Agency of Canada and is likely to become commonplace throughout the 
world249. Additionally, sequence based methods, such as multi-locus sequence typing 
(MLST) and whole genome sequencing (WGS; specifically single nucleotide 
polymorphism (SNP) typing) have gained interest specifically to study evolutionary 
relationships between various C. difficile strains (phylogeny)17. Overall, different 
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lineages can be discriminated and several different PCR ribotypes have been shown to 
be closely related to the epidemic types using these sequence based methods98,231. WGS 
is also used to study transmission and outbreaks25,232, although this approach can be 
costly and is mainly performed retrospectively. Relatedness of strains in an outbreak 
setting is more commonly performed using multi-locus variable-number tandem repeat 
analysis (MLVA)17.  
 
Box 2. Antibiotic resistance of Clostridum difficile.  
Most antimicrobial compounds target metabolically active cells and have limited or no 
activity against dormant cells, such as spores. This intrinsic resistance of spores ensures 
that C. difficile can persist in the presence of antibiotics or the host immune 
system250,251. C. difficile also demonstrates extensive acquired antimicrobial 
resistance9,252. Interestingly, C. difficile vegetative cells are sensitive to teicoplanin and 
vancomycin, despite harbouring a genomic region that resembles a vanG glycopeptide 
resistance cluster9,253. This cluster can confer vancomycin resistance to a heterologous 
host, but why it is not functional in C. difficile is unclear254. The mobile genome of C. 
difficile (comprising transposons, insertion sequences and (pro)phages) probably 
contributes to antibiotic resistance because these elements commonly contain 
resistance determinants9,255. For example, the Tn6218 element of C. difficile contains a 
cfr-like gene that can confer resistance to peptidyl transferase inhibitors such as 
linezolid256 and the Tn5397 element carries a tetracyclin resistance determinant257. 
Reduced susceptibility or resistance to the commonly used antibiotics (vancomycin, 
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metronidazole and fidaxomicin) has been noted258–261. Although this is cause for 
concern, the clinical relevance of resistance to these antibiotics so far is limited. 
However, C. difficile antibiotic resistance is only part of the reason why C. difficile has 
been classified as an Urgent Antibiotic Resistance Threat by the US Centers for Disease 
Control and Prevention262. Other major factors include that the bacterium affects 
people treated by antibiotics for other infections, the ageing of the general population 
and the emergence of epidemic types, such as PCR ribotype 027. At least in this 
ribotype, epidemic lineages are associated with resistance against fluoroquinolones8; 
although this class of antibiotics is not used for the treatment of C. difficile infections, 
the antibiotics can select for C. difficile when used to treat other infections. 
Fluoroquinolone resistance is also common in other PCR ribotypes263.  
 
Box 3. Infection control and prevention of Clostridium difficile infection  
• Ensure rapid diagnostic testing of patients with diarrhoeal illness acquired in the 
hospital or associated with antimicrobial therapy 
• A hospital-based infection control programme combined with active surveillance 
can help to decrease the incidence of Clostridium difficile infection (CDI); locally 
defined thresholds/triggers for the addition of enhanced control measures are 
needed 
• Antibiotic stewardship, including restriction of specific high-risk antimicrobials 
(such as clindamycin, cephalosporins and fluoroquinolones), is recommended to 
reduce the risk of CDI 
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• Patient isolation and contact precautions (including hand hygiene with soap and 
water) should be maintained until at least the diarrhoea has resolved 
• If isolation in a single room is not possible, alternatives are segregation within 
wards and/or cohorting of cases 
• Disinfection of environmental surfaces is recommended using chlorine-releasing 
agents as a minimum in clinical areas with CDI cases 
• Educate healthcare personnel, cleaning staff and patient visitors on contact 
precautions to minimize the transmission of spores 
 
 
Figure 1. Clostridium difficile. a | Typical image of C. difficile colonies on a blood agar 
plate. b | Phase contrast microscopy image of a C. difficile culture with vegetative cells 
(elongated rods), phase dark spores (subterminal dark spots) and phase bright spores 
(bright ellipsoids). Inset: Gram stain of culture. c |Scanning electron micrograph of C. 
difficile spores. d |Endoscopic picture of pseudomembranous colitis caused by C. 
difficile. Healthy colon tissue is pink, pseudomembranes resulting from C. difficile 
infection are yellow.  
 
Figure 2. Stages of the Clostridium difficile lifecycle in the human gastrointestinal tract. 
Three sources of infection (healthcare, animal and environmental) are indicated. A 
range of host factors influence the C. difficile lifecycle, and the relative numbers of 
spores and vegetative (metabolically active) cells in the gut (as indicated in the figure). 
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Note that passage through the stomach eliminates most vegetative cells (but spores 
survive), and spores germinate and grow out in the duodenum. In the caecum and 
colon, C. difficile starts producing spores again, but during infection vegetative cells are 
also excreted by the patient. Toxin is produced in the colon. As C. difficile is an obligate 
anaerobic bacterium, transmission occurs primarily via spores. SCFA: short chain fatty 
acids (such as butyrate). 
 
Figure 3. Innate immune response of host cells towards Clostridium difficile. C. difficile 
elicits the innate immune response via at least four different effectors, leading to the 
induction of pro-inflammatory cytokines and chemokines via NF-κB and transcription 
factor AP-1. Toxins act via NLRP3 (NOD-, LRR- and pyrin domain-containing 3) 
inflammasome-dependent and independent pathways. Flagellin and surface layer 
protein A (SlpA) act via myeloid differentiation primary response protein MyD88 
(MyD88)-dependent pathways through Toll-like receptor 4 (TLR4) and TLR5, 
respectively. The nucleotide-binding oligomerization domain-containing protein 1 
(NOD1)-dependent pathway of induction most likely detects fragments of peptidoglycan 
(PG*), derived from the cell wall of C. difficile. Dashed lines indicate indirect effects.  
  
Figure 4. Regulation of the Clostridium difficile toxins. a | Schematic representation of 
the pathogenicity locus (PaLoc) and the flanking regions with regulatory interactions of 
C. difficile. Boxes with arrows indicate open reading frames with the direction of the 
arrows showing the direction of transcription. Toxin genes (tcdA and tcdB) are shaded in 
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blue, regulatory genes are in orange (positive) and green (negative); tcdE is in yellow 
and genes located outside the PaLoc are in grey. Dashed arrows indicate the production 
of protein from a gene transcript. Other regulators (Sigma D (SigD), the nutritional 
repressor CodY (known as GTP-sensing transcriptional pleiotropic repressor CodY), 
catabolite control protein A (CcpA), Stage 0 sporulation protein A (Spo0A) and quorum 
sensing (QS)) that affect toxin gene transcription (boxed) mostly act via expression of 
the tcdR gene. The TcdR protein is involved in the initiation of the production of TcdA 
and TcdB. b | Schematic representation of the binary toxin locus (CdtLoc) and flanking 
regions with regulatory interactions. Boxes with arrows indicate open reading frames 
with arrows showing the direction of transcription. The cdtA and cdtB toxin genes are 
shaded in blue, the regulatory gene cdtR is in orange and genes located outside the 
CdtLoc are in grey.  
 
Figure 5. Structure and function of the large clostridial toxins. a | Schematic of the 
TcdA/TcdB primary structure highlighting the four functional domains; the 
glucosyltransferase domain (GTD; red), the autoprotease domain (APD; blue), the 
delivery domain (yellow) and the combined repetitive oligopeptides (CROPS) domain 
(green) that binds carbohydrates on the host cell surface to facilitate bacterial entry. b | 
Overlay of an electron microscopy reconstruction of the structure of TcdA with the X-ray 
crystal structure of TcdA lacking CROPS (Protein Data Bank code 4R04). Colour-coding 
reflects the domain structure in panel a. c | The discrete structural and functional 
domains of the toxins contribute to a multi-step mechanism of intoxication. Toxins bind 
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to one or more receptors (carbohydrate and/or protein) on the cell surface (step 1) and 
are internalized by receptor mediated endocytosis (step 2). As the endosome matures, 
the V-ATPase contributes to a decrease in pH (step 3). The acidic pH causes a 
conformational change in the toxin delivery domain, resulting in pore formation (step 4) 
and the translocation of the APD and GTD into the cytosol (step 5). Inositol 
hexakisphosphate (InsP6) binds and activates the APD resulting in the release of the 
GTD (step 6), which can inactivate Rho family proteins (step 7) to cause apoptosis and 
cytopathic ‘rounding’ effects. d | At concentrations >0.1 nM, TcdB can promote Ras-
related C3 botulinum toxin substrate 1 (Rac1) activation (step 1) and complex formation 
between p22phox (also known as cytochrome b-245 light chain), NADPH oxidase 1 
(NOX1), NADPH oxidase activator 1 (NOXA1), NADPH oxidase organizer 1 (NOXO1) and 
Rac1 on the endosomal membrane to form the NOX complex (step 2). The fully 
assembled NOX complex generates superoxide by transferring an electron from NADPH 
to molecular oxygen (step 3). Superoxide generation leads to the production of reactive 
oxygen species (ROS), which — at high levels — promote necrosis by causing 
mitochondrial damage, lipid peroxidation and protein oxidation (step 5). 
 
Figure 6. Histopathology of Clostridium difficile infection in a mouse model. 
Histopathological analysis of haematoxylin and eosin-stained caecal and colonic tissues 
collected from mice infected with a wild-type PCR ribotype 027 strain (TcdA+/TcdB+), 
infected with an isogenic double tcdA and tcdB mutant (TcdA-/TcdB-), or mock-infected 
with phosphate buffered saline (Mock). Note that both wild-type and double mutant 
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strains contain an intact binary toxin locus. Arrows indicate major histological 
differences; oedema and polymorphonuclear cell influx into the lamina propria (black), 
erosion of crypts and goblet cell loss (yellow) and hyperplasia (white).  
 
Figure 7. Mechanism of action of Clostridium difficile transferase (binary toxin). 
Clostridium difficile transferase (CDT) is a binary toxin consisting of the CDTa ADP-
ribosyltransferase (in red) and the CDTb protein (in yellow and green). The monomeric 
form of CDTb binds to the lipolysis-stimulated lipoprotein receptor (LSR)264, which is 
found in many tissues including the gut. CDTb undergoes proteolytic activation and 
oligomerizes to form a heptameric prepore, which facilitates the binding of CDTa to the 
prepore-receptor complex. This complex enters cells by endocytosis and as the 
endosome matures, the V-ATPase contributes to a decrease in pH. The low pH of the 
endosome triggers pore formation and the translocation of CDTa into the cell. Once in 
the cytosol CDTa, ribosylates actin at arginine 177, resulting in a dual effect whereby G-
actin polymerization is inhibited and F-actin depolymerization is favoured, which leads 
to the complete destruction of the actin cytoskeleton and, ultimately, cell death135,141. 
Inset: structure of CTDa (Protein Data Bank code 2WN7).  
  
Figure 8. Diagnosis and treatment options for Clostridium difficile infections. When a 
patient is suspected of having Clostridium difficile infection (CDI), the recommended 
option is to detect toxins of C. difficile in the stool. Several diagnostic algorithms have 
been condensed into this figure265. Treatment options indicated here are based on 
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reports by Leffler and Lamont14 and Debast et al.155 *Fidaxomicin is a treatment option 
if the risk of recurrence is high, but not for complicated CDI. For moderate CDI, 
metronidazole is given orally, in severe cases intravenously. Hospitalization refers to 
admission as a result of CDI (not as a result of comorbidities; patients might already be 
hospitalized). Note that recurrence after clinical cure (resolution of symptoms) can be 
observed. Faecal microbiota transplant is an effective but non-standard form of 
treatment and, therefore, indicated with a dashed line.  
 
Figure 9. Faecal microbiota transplant. In faecal microbiota transplant (FMT), faecal 
material from a healthy donor is harvested. The material is processed (blending, 
filtration) into pills or a solution. As part of this process, a check for the presence of 
pathogenic and multi-drug resistant organisms is performed. The processed material 
can be stored prior to (one-off) administration by nasoduodenal infusion, colonoscopic 
infusion or rectal enema for solution formulations or orally for pill formulations. 
Antibiotic treatment generally precedes the administration of the FMT to reduce C. 
difficile levels. Alongside FMT, [Au:OK?] efforts are ongoing to standardize 
bacteriotherapy. On the basis of microbiome and metabolome analyses, signatures of 
resistance to colonization by C. difficile are identified. After harvesting faecal material 
from healthy donors, species identified in these microbiome signatures or believed to 
be responsible for the metabolomic signature are cultured. Defined mixtures of these 
strains are tested for safety and ability to confer colonization resistance in preclinical 
trials and subsequently validated in clinical studies. Colored bars indicate microbial 
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diversity of the microbiome, which is severely reduced in the patient with CDI compared 
with the healthy subject. 
 
Figure 10. Cost per case of Clostridium difficile infection. The data depicted in this 
figure are from Ghantoji et al.219 (indicated with a superscript 1) and Vonberg et al.216 
(indicated with a superscript 2); last names and years on the right in the panel indicate 
the original studies described in these. Conversion between respective US$ and € 
amount is done based on 2008 exchange rates. Note that several studies have estimated 
the cost of C. difficile infections more recently220,266,267. IBD: inflammatory bowel 
disease. ICU: intensive care unit.  
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Table 1. Selected agents for the treatment and prevention of CDI in clinical trial.  
Agent (manufacturer) Indication Notes Clinical trial 
identifier 
 
Phase III   
Actoxumab and 
bezlotoxumab alone or 
in combination (Merck) 
Prevention of 
recurrent CDI 
Anti-toxin A (MK-3415) and anti-toxin B (MK-6072) 








Cadazolid (Actelion) Treatment  Hybrid antibiotic molecule, comprising fluoroquinolone and 





Prevention  Vaccine containing toxoids of toxin A and B (TcdA and TcdB) 
from C. difficile  
NCT01887912
Phase II   
IC84 vaccine (Valneva) Prevention  Vaccine comprising recombinant protein of two truncated 
toxins A and B (TcdA and TcdB) from C. difficile 
 NCT02316470








recurrent CDI  
Oral microbiome therapeutic (mixture of bacterial spores) 
granted orphan drug designation 
 NCT02437500
SMT19969 (Summit Plc) Treatment  Oral non-absorbable antibiotic with a narrow spectrum of 
activity and high selectivity for C. difficile 
 
 NCT02092935
C. difficile vaccine 
(Pfizer) 






Prevention  Class A β-lactamase designed to protect gut microbiota from 
the action of systemically administered β-lactam antibiotics 
that might otherwise predispose for CDI 
NCT02563106
VP20621(Shire) Prevention of 
recurrent CDI 
Orally administered non-toxigenic C. difficile
 
 NCT01259726
Phase I   
PolyCAb (Micropharm) Treatment of 
severe CDI 
Polyclonal antibodies against C. difficile given intravenously Not available
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This Primer describes the mechanisms underlying the serious effects of Clostridium 
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